ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
11:33 AM ET on Apr 28, 2015
Delayed at least 20 minutes.
Provided by eSignal.
Apr 22, 2015
ChemoCentryx to Hold First Quarter 2015 Financial Results Conference Call on Wednesday, May 6, 2015
Apr 20, 2015
ChemoCentryx Initiates Clinical Trial of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, in Pancreatic Cancer
Mar 12, 2015
ChemoCentryx Reports Fourth Quarter 2014 Financial Results and Provides Corporate Update
View all »Events & Presentations
May 6, 2015 at 5:00 PM ET
ChemoCentryx, Inc. First Quarter 2015 Financial Results Conference Call
^ Return to Top